Flat rate shipping — $9 dry goods · $13 chilled gel 🌿

science safety

TSH Testing for Sea Moss Users: A 12-Week Lab Schedule

A clinical, RACGP-aware 12-week TSH testing schedule for adults starting sea moss: baseline, week 6, week 12: with antibody, free T4/T3, and Medicare item guidance.

General information, not medical advice. Sea moss contains iodine. Ask your GP before use if you have a thyroid condition, take medication, or are pregnant or breastfeeding. Quality & Testing.

## Introduction: Why a generic thyroid panel is not enough Most Australians who try sea moss never measure their thyroid before, during, or after. The product is sold as a food, the iodine load is invisible on the label, and the standard advice is the vague "check with your doctor." That advice is structurally inadequate. *Chondrus crispus* is one of the most variable iodine sources in the consumer food supply. A single 45 g dried serving can deliver up to 2,100 mcg of iodine, almost double the adult tolerable upper intake level of 1,100 mcg per day set by Food Standards Australia New Zealand (FSANZ, 2008; NHMRC, 2006). Without a measured baseline and a structured retest schedule, a slow rise in TSH is indistinguishable from "I'm just a bit tired this month." This article gives you the schedule the wellness market never publishes: a 12-week thyroid monitoring plan calibrated to the biochemistry of iodine adaptation, the Royal Australian College of General Practitioners (RACGP) and Royal College of Pathologists of Australasia (RCPA) testing conventions, and the Medicare Benefits Schedule (MBS) items your GP will actually code. It is written for sea moss users, but the framework applies to any new iodine source: kelp capsules, nori-heavy diets, povidone-iodine exposure, or contrast media. The central claim we will defend with evidence: **the thyroid's autoregulatory escape from a sudden iodine load normally completes within 10 to 14 days; if your TSH at week 6 has risen by more than 2.0 mIU/L from baseline, the escape has failed and continued use is no longer a low-risk decision** (Wikipedia contributors, 2025; Aung & Kawamura, 2023). ## Why sea moss demands its own monitoring framework ### Iodine variability is the story A standard supplement label tells you "150 mcg of iodine." A sea moss jar does not. Iodine content in dried *Chondrus crispus* varies by harvest location, season, water temperature, and processing, and published case data show that kelp- and seaweed-containing dietary products have produced thyroid dysfunction at doses of 1,500 to 1,800 mcg per day within 10 to 20 days of starting (Eliason, 2014). One case documented TSH rising from 0.05 mU/L (transient thyrotoxicosis) to 64.0 mU/L (frank hypothyroidism) over 90 days of exposure to a kelp-based diet, with resolution only after three to four months of discontinuation and levothyroxine support (Eliason, 2014). The implication is operational: if you cannot read a per-lot iodine value (in mcg/g) off your supplier's certificate of analysis, you are dosing blind, and a monitoring schedule is the only safety net. Seamossvibes publishes the per-lot ICP-MS iodine value on every batch; the dosage guide translates that to per-serving mcg so the maths is on paper, not in your head. ### Wolff-Chaikoff and Jod-Basedow set the testing windows When the thyroid is suddenly flooded with iodide, it transiently shuts down organification of iodine to thyroid hormone: the **Wolff-Chaikoff effect**. In a healthy gland this suppression lasts "several days (around 10 days)," after which sodium-iodide symporter (NIS) expression falls, intracellular iodide drops below the inhibitory threshold, and normal hormone synthesis resumes: the so-called **escape** (Wikipedia contributors, 2025; Eng et al., 1999). Failure to escape produces persistent hypothyroidism. In the Aung and Kawamura (2023) case of failure to escape after ethiodized-oil chemoembolization, TSH was 2.20 mIU/mL at exposure, rose to 4.88 by day 14, 7.26 by day 35, 11.0 by day 42 (overt hypothyroidism), and peaked at 38.4 by day 69 before normalising around day 91. That arc: a measurable rise by week 2, frank disease by week 6, peak by week 10: is exactly why we test at baseline, week 6, and week 12. The mirror-image risk is **Jod-Basedow**: in patients with nodular goitre, latent Graves disease, Hashimoto thyroiditis, prior thyroid surgery, or chronic kidney disease, the same iodine load can escape negative feedback and trigger thyrotoxicosis rather than hypothyroidism (Leung & Pearce, 2023). Both directions need to be visible in your lab data, which is why the panel is not TSH alone. ## The 12-week schedule ### Visit 1 Baseline (Week 0, before the first dose) | Test | MBS item (typical) | Why it matters | | --- | --- | --- | | TSH | 66716 | Sets the reference point for the 2.0 mIU/L delta rule | | Free T4 | 66719 reflex | Distinguishes overt (low FT4) from subclinical (normal FT4) hypothyroidism (Walsh, 2016) | | Free T3 | 66719 reflex | Useful if TSH suppressed or if T3 toxicosis suspected | | TPO antibodies | Medicare-restricted; covered when TSH is abnormal | Stratifies progression risk: 4.3% per year vs 2.1% in antibody-negative subjects (Hollowell et al. via Walsh, 2016) | | TgAb (thyroglobulin antibody) | As clinically indicated | Adds sensitivity for Hashimoto when TPO is negative but clinical suspicion remains | The RCPA position statement on adult thyroid function testing makes the reflex pattern explicit: TSH is the initial test; if TSH is abnormal, free T4 should be requested, and "free T4 and/or free T3 should never be requested in isolation" (Royal College of Pathologists of Australasia, n.d.). Asking your GP for the full panel up front is reasonable when you are deliberately introducing an iodine source: the panel is justified by intervention, not symptom-chasing. ### Visit 2 Week 6 (Early adaptation check) Repeat **TSH and free T4**. The 6-week interval is not arbitrary: Walsh (2016) writes in the *Medical Journal of Australia* that "serum TSH testing should be repeated 6 8 weeks later, together with free T4 and TPOAb" after any intervention affecting thyroid function. Six weeks is also the standard interval for assessing levothyroxine dose changes, because TSH equilibration takes that long after a thyroidal perturbation. ### Visit 3 Week 12 (Steady-state confirmation) Repeat **TSH and free T4**. By week 12, the Wolff-Chaikoff escape should have completed in any healthy gland; persistent elevation at this checkpoint signals a problem that does not resolve with "more time." If antibodies were positive at baseline, repeat TPO at week 12; if negative, you do not need to retest antibodies until the annual review. ### Visit 4 Annual (or sooner if symptomatic) For TPO-positive patients with normal TSH, annual TSH monitoring is appropriate (Walsh, 2016). For TPO-negative euthyroid patients on a stable sea moss protocol, three-yearly TSH plus symptom-triggered testing is defensible. Seamossvibes recommends an annual recheck regardless, because batch iodine values vary lot to lot and your average exposure today is not your average exposure in 12 months. ## The three lab patterns that demand discontinuation Not every wobble in your numbers means stop. Three specific patterns do. ### Pattern 1 TSH rises more than 2.0 mIU/L from baseline at week 6, even if still in range If your baseline TSH was 1.4 mIU/L and your week-6 TSH is 3.6 mIU/L, both values are technically inside the Australian reference range of approximately 0.4 to 4.0 mU/L (Walsh, 2016). The 2.0-point delta is the meaningful signal: it indicates the thyroid is being driven harder to maintain output, which is the earliest evidence that the iodine load is straining the gland. The clinically prudent action is to pause sea moss, retest at 6 weeks, and consult your GP if the trajectory does not reverse. ### Pattern 2 TSH above the upper reference limit at any visit, regardless of free T4 A TSH above approximately 4.0 mU/L is subclinical hypothyroidism if free T4 is normal, or overt hypothyroidism if free T4 is low (Walsh, 2016). Overt hypothyroidism and subclinical hypothyroidism with TSH greater than 10 mU/L are treatment indications without further investigation, per the MJA guidance. Continuing the suspected trigger is medically indefensible. ### Pattern 3 TSH suppressed below the lower reference limit A TSH below approximately 0.4 mU/L raises the Jod-Basedow scenario: iodine-induced thyrotoxicosis in a patient with a previously unrecognised autonomous nodule or latent Graves disease (Leung & Pearce, 2023). This is more dangerous than the hypothyroid pattern because it can precipitate atrial fibrillation, particularly in older adults. Discontinue immediately and request urgent endocrinology review. > "Initial therapy for overt hyperthyroidism should be started without delay. Patients with nodular thyroid disease appear to have a markedly increased risk for developing iodine-induced thyrotoxicosis when exposed to excess iodine." > Leung, A. M., & Pearce, E. N. (2023). *Jod-Basedow Syndrome.* StatPearls. ## What Medicare actually covers The Medicare Benefits Schedule (MBS) is unambiguous about what it pays for, and it is worth knowing before you sit in the GP's room. | MBS item | What it covers | When it applies | | --- | --- | --- | | 66716 | TSH measurement | Always covered when clinically indicated | | 66719 | TSH plus free T4 and/or free T3 | When TSH is outside the normal reference range; or when the request indicates monitoring of thyroid disease, sick euthyroid syndrome investigation, amenorrhoea/infertility workup, dementia or psychiatric illness investigation, or suspected pituitary dysfunction (Australian Government Department of Health, n.d.) | | Thyroid antibodies (TPO, TgAb) | Antibody panel | Restricted; typically reimbursable when TSH is abnormal or when investigating suspected autoimmune thyroid disease | The practical workflow: at baseline, ask your GP to request TSH with reflex to free T4 and free T3, and to add TPO antibodies given you are about to introduce a high-variability dietary iodine source. The MBS criteria for 66719 explicitly include "monitoring thyroid disease" and "drug interactions": a documented intent to monitor an iodine intervention falls within the spirit of the clinical indication, but the GP holds discretion on coding. If a test is not bulk-billed, the schedule fee for 66719 is $34.80 with a 75% benefit of $26.10 and an 85% benefit of $29.60 (Australian Government Department of Health, n.d.). The total out-of-pocket for the full 12-week schedule is rarely prohibitive even without bulk-billing. ## Why TSH alone is insufficient when antibodies are positive The classic "TSH first, free T4 only if TSH is abnormal" approach is appropriate for general screening but becomes inadequate the moment thyroid antibodies enter the picture. A patient with positive TPO antibodies and normal TSH carries an annual progression risk to overt hypothyroidism of approximately 2 to 5%, depending on age, sex, and baseline TSH (Walsh, 2016; American Thyroid Association patient guidance). In the European Thyroid Association 2013 guideline on subclinical hypothyroidism, repeat thyroid function tests are recommended every 6 to 12 months in antibody-positive subjects, with shorter intervals after any intervention that perturbs iodine status (Pearce et al., 2013). When sea moss is added to a TPO-positive baseline, two mechanisms stack: 1. **Substrate provision**: the gland receives more iodine raw material, which in an autoimmune background can accelerate cellular damage and antibody-mediated destruction. 2. **Wolff-Chaikoff failure risk**: TPO-positive glands are over-represented in the population that fails to escape the acute Wolff-Chaikoff effect, producing persistent rather than transient hypothyroidism (Wikipedia contributors, 2025). The defensible protocol for a TPO-positive patient is: do not start sea moss without endocrinologist input; if started, retest TSH and free T4 at week 4 (not week 6), and at week 8, and at week 12; pause at any rise greater than 1.0 mIU/L (a tighter threshold than the antibody-negative 2.0 mIU/L rule). For a full walkthrough of the Hashimoto-specific protocol, see our companion piece on [Hashimoto's sea moss protocol](/blogs/learn/science-safety/hashimotos-sea-moss-protocol). ## On reverse T3, euthyroid sick syndrome, and tests not to order The wellness market routinely promotes **reverse T3 (rT3)** as a way to diagnose "hidden hypothyroidism." The Royal College of Pathologists of Australasia position statement is direct: "There are no situations where measurement of reverse T3 is validated" (Royal College of Pathologists of Australasia, n.d.). Reverse T3 rises in non-thyroidal illness (also called euthyroid sick syndrome): sepsis, trauma, prolonged fasting, anorexia: but it does not reliably differentiate hypothyroid sick syndrome from euthyroid sick syndrome and is not a standalone diagnostic (Chopra et al., 1996; Adler & Wartofsky, 2007). If you read a blog telling you to order rT3 to "diagnose your thyroid problem from sea moss," you are reading marketing, not medicine. The same applies to whole-day saliva cortisol panels and proprietary "thyroid-adrenal" stack tests sold by unregulated labs. The TSH, free T4, free T3, TPO panel covered by the MBS is what an endocrinologist actually uses to make a decision. Euthyroid sick syndrome matters in a different way: if your week-6 labs are drawn during an acute illness, the TSH and T3 values may be transiently abnormal independent of iodine exposure. Reschedule the blood draw 2 to 3 weeks after recovery if you have been febrile, hospitalised, or significantly underfed in the preceding fortnight. ## Decision checkpoint: should you draw blood this week? Use this self-assessment before booking the next blood test. It mirrors what an integrative practitioner would walk through verbally. - [ ] I have a documented baseline TSH and free T4 from the 4 weeks before my first sea moss dose. - [ ] I know the per-serving iodine of my current lot in mcg (from the supplier COA, not a guess). - [ ] My current daily iodine intake from all sources (sea moss + iodised salt + dairy + seafood + supplements) is under 1,100 mcg. - [ ] I am not currently acutely unwell, febrile, hospitalised, or significantly underfed (which would distort thyroid labs via euthyroid sick syndrome). - [ ] I am not taking biotin at doses above 5 mg per day in the 48 hours before the draw (high-dose biotin causes falsely low TSH and falsely high free T4 on many immunoassays). - [ ] I have not had iodine-containing contrast media (CT scan with contrast, angiography) in the past 4 to 6 weeks. - [ ] I have not started or stopped levothyroxine, amiodarone, lithium, or carbimazole in the past 6 weeks. If you cannot tick all seven, fix what you can and reschedule. A blood test drawn against a distorted baseline is a worse decision aid than no test at all. ## A worked example: the 12-week arc A 42-year-old AU woman, antibody-negative, baseline TSH 1.6 mU/L and free T4 14 pmol/L. She starts on a 2 g daily dried serving of Seamossvibes Saint Lucian *Chondrus crispus*, lot 2026-04-A, measured iodine value 187 mcg/g: a per-serving dose of 374 mcg. Total iodine including diet: approximately 580 mcg/day, well under the 1,100 mcg UL. - **Week 6:** TSH 2.1 mU/L (rise of 0.5), free T4 13.5 pmol/L. Delta below 2.0 mIU/L, both values in range: continue with the current protocol. - **Week 12:** TSH 2.0 mU/L (rise of 0.4 from baseline), free T4 14 pmol/L. Stable: convert to annual monitoring with a single TSH at 12 months. Contrast with a second woman, TPO-positive, baseline TSH 2.8 mU/L. Same protocol: - **Week 4:** TSH 3.4 mU/L (rise of 0.6). Within the tighter TPO-positive 1.0 mIU/L threshold but trending: continue with close watch. - **Week 8:** TSH 4.6 mU/L (rise of 1.8). Above upper reference limit. Discontinue sea moss, retest at 6 weeks, refer to endocrinologist. The numbers are illustrative, not prescriptive: your numbers will be your numbers: but the decision logic is the framework. ## When sea moss should not be on your shelf at all Even with perfect monitoring, some patients should not introduce sea moss without specialist supervision: - Active Graves disease, toxic nodular goitre, or untreated hyperthyroidism: Jod-Basedow risk is unacceptable - Pregnancy or active attempt to conceive: fetal thyroid is exquisitely iodine-sensitive. Defer to obstetric guidance and stick to the iodine-supplemented prenatal formula your obstetrician recommends - Recent radioactive iodine therapy or thyroidectomy: total iodine status is being actively managed - Concurrent amiodarone, lithium, or carbimazole: these drugs already disrupt thyroid iodine handling and add an unpredictable interaction - Severe renal impairment (eGFR < 30): iodine excretion is delayed and accumulation risk rises If you are unsure where you sit, the conservative default is to defer until you have an endocrinology consult. ## Conclusion: numbers, not vibes Sea moss is not benign. It is a high-variability iodine source delivered in a food matrix, and the marketing system around it does not encourage measurement. The cost of a structured 12-week TSH schedule: three blood draws, a Medicare-coded panel, and a baseline-to-week-12 delta calculation: is the cheapest insurance policy available for your thyroid. The clinical-honesty position is simple. Baseline before you start. Retest at week 6 and week 12. If TSH rises more than 2.0 mIU/L from baseline, pause and consult. If antibodies are positive, halve the thresholds and double the testing frequency. Reverse T3 is not a validated test. Euthyroid sick syndrome is a real confound. And if your supplier cannot give you a per-lot iodine value in mcg/g, your monitoring plan has a hole in it that no blood test can close. For the dose-titration arithmetic that pairs with this monitoring plan, see the [micro-dose titration protocol](/blogs/learn/how-to-use/micro-dose-titration-protocol). For the deeper iodine-physiology background, see [iodine and thyroid safety](/blogs/learn/science-safety/iodine-thyroid-safety) and the [selenium-iodine pairing](/blogs/learn/science-safety/selenium-iodine-pairing) brief. **Mandatory disclosures** The adult tolerable upper intake level (UL) for iodine is 1,100 mcg/day. Sea moss iodine concentration varies by lot: always check the per-serving iodine on your batch COA. Sea moss is a bioaccumulator of arsenic, lead, cadmium, and mercury. Choose a supplier that publishes batch-level ICP-MS results with HPLC-ICP-MS arsenic speciation. Seamossvibes publishes a COA per lot. The term sea moss commercially includes *Chondrus crispus*, *Gracilaria spp.*, and *Eucheuma cottonii*. Seamossvibes uses wild-harvested *Chondrus crispus* from Saint Lucia, verified per lot. Consult your GP, endocrinologist, or registered practitioner before introducing sea moss if you have thyroid disease, take anticoagulants, ACE inhibitors, metformin, or potassium-sparing diuretics, or are pregnant or breastfeeding. Always read the label and follow directions for use. This product is not intended to diagnose, treat, cure, or prevent any disease. ## Next step [Take the Mineral Blueprint](/vitality/assessment) to map your current iodine intake against your thyroid risk profile, then book the baseline TSH panel before your first dose: a 12-week monitoring plan only works if week 0 is on paper. ## References - Adler, S. M., & Wartofsky, L. (2007). The nonthyroidal illness syndrome. *Endocrinology and Metabolism Clinics of North America*, 36(3), 657 672. - Aung, E. T., & Kawamura, J. (2023). Iodine-induced hypothyroidism after chemoembolization with ethiodized oil: A case of failure to escape from the Wolff-Chaikoff effect. *Cureus*, 15(5). https://pmc.ncbi.nlm.nih.gov/articles/PMC10284623/ - Australian Government Department of Health. (n.d.). *Medicare Benefits Schedule Item 66719*. https://www9.health.gov.au/mbs/fullDisplay.cfm?q=66719&qt=item&type=item - Chopra, I. J., Hershman, J. M., Pardridge, W. M., & Nicoloff, J. T. (1996). Reverse T3 does not reliably differentiate hypothyroid sick syndrome from euthyroid sick syndrome. *Thyroid*, 6(4), 281 285. https://pubmed.ncbi.nlm.nih.gov/8808092/ - Eliason, B. C. (2014). Thyroid dysfunction following a kelp-containing marketed diet. *BMJ Case Reports*. https://pmc.ncbi.nlm.nih.gov/articles/PMC4216876/ - Eng, P. H. K., Cardona, G. R., Fang, S. L., Previti, M., Alex, S., Carrasco, N., Chin, W. W., & Braverman, L. E. (1999). Escape from the acute Wolff-Chaikoff effect is associated with a decrease in thyroid sodium/iodide symporter messenger ribonucleic acid and protein. *Endocrinology*, 140(8), 3404 3410. https://academic.oup.com/endo/article/140/8/3404/2990434 - Endocrine Society of Australia / Hormones Australia. (n.d.). *Hypothyroidism*. https://www.hormones-australia.org.au/endocrine-diseases/hypothyroidism/ - Food Standards Australia New Zealand. (2008). *Consideration of mandatory fortification with iodine for Australia and New Zealand Safety assessment*. https://www.foodstandards.gov.au/sites/default/files/food-standards-code/proposals/Documents/P1003%20SD9%20-%20Safety%20Assessment.pdf - Koulouri, O., & Gurnell, M. (2019). Challenges in interpreting thyroid stimulating hormone results in the diagnosis of thyroid dysfunction. *Journal of Thyroid Research*, 2019. https://pmc.ncbi.nlm.nih.gov/articles/PMC6778876/ - Leung, A. M., & Pearce, E. N. (2023). *Jod-Basedow syndrome*. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK544277/ - National Health and Medical Research Council. (2006). *Nutrient reference values for Australia and New Zealand: Iodine*. https://www.nhmrc.gov.au/sites/default/files/images/nutrient-refererence-dietary-intakes.pdf - Pearce, S. H. S., Brabant, G., Duntas, L. H., Monzani, F., Peeters, R. P., Razvi, S., & Wemeau, J. L. (2013). 2013 ETA guideline: Management of subclinical hypothyroidism. *European Thyroid Journal*, 2(4), 215 228. https://pmc.ncbi.nlm.nih.gov/articles/PMC3923601/ - Royal Australian College of General Practitioners. (n.d.). *Management of subclinical hypothyroidism First do no harm: A guide to choosing wisely in general practice*. https://www.racgp.org.au/getattachment/db9752c6-2814-4d25-b433-6133131dbc5f/Management-of-subclinical-hypothyroidism.aspx - Royal College of Pathologists of Australasia. (n.d.). *Thyroid function testing for adult diagnosis and monitoring Position statement*. https://www.rcpa.edu.au/Library/College-Policies/Position-Statements/Thyroid-Function-Testing-for-Adult-Diagnosis-and-M - Walsh, J. P. (2016). Managing thyroid disease in general practice. *Medical Journal of Australia*, 205(4), 179 184. https://doi.org/10.5694/mja16.00545 - Wikipedia contributors. (2025). *Wolff Chaikoff effect*. Wikipedia. https://en.wikipedia.org/wiki/Wolff%E2%80%93Chaikoff_effect

Ready to start?

Turn what you learned into a daily ritual

Explore formats and product details, then check the physical label before use.

Explore products →

Listed ingredients · Storage guidance

Read next

  • Listed product details
  • Available report scope
  • Secure checkout
  • Shipping policy available